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Non–small cell lung cancers (NSCLCs) frequently express estrogen receptor (ER) β, and estrogen signaling is active in
many lung tumors. We investigated the ability of genes contained in the prediction analysis of microarray 50 (PAM50)
breast cancer risk predictor gene signature to provide prognostic information in NSCLC. Supervised principal
component analysis of mRNA expression data was used to evaluate the ability of the PAM50 panel to provide
prognostic information in a stage I NSCLC cohort, in an all-stage NSCLC cohort, and in The Cancer GenomeAtlas data.
Immunohistochemistry was used to determine status of ERβ and other proteins in lung tumor tissue. Associations
with prognosis were observed in the stage I cohort. Cross-validation identified seven genes that, when analyzed
together, consistently showedsurvival associations. In pathway analysis, the seven-gene panel described onenetwork
containing the ER and progesterone receptor, as well as human epidermal growth factor receptor (HER)2/HER3 and
neuregulin-1. NSCLC cases also showed a significant association between ERβ and HER2 protein expression. Cases
positive for HER2 expression were more likely to express HER3, and ERβ-positive cases were less likely to be both
HER2 and HER3 negative. Prognostic ability of genes in the PAM50 panel was verified in an ERβ-positive cohort
representing all NSCLC stages. In The Cancer Genome Atlas data sets, the PAM50 gene set was prognostic in both
adenocarcinoma and squamous cell carcinoma, whereas the seven-gene panel was prognostic only in squamous cell
carcinoma. Genes in the PAM50 panel, including those linking ER and HER2, identify lung cancer patients at risk for
poor outcome, especially among ERβ-positive cases and squamous cell carcinoma.
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Lung cancer is the leading cause of cancer-related mortality in the
United States. Complete surgical resection of early stage non–small
cell lung cancer (NSCLC) provides the best chance for cure, but there
is significant risk of relapse, with a 5-year survival rate for patients
with stage IA disease of only 73% and 58% for stage IB disease [1].
Adjuvant therapy for stage I disease is not currently recommended
[2]. Identifying patients at high risk of recurrence based on the
biology of their lung tumors could identify those in need of adjuvant
treatment, and a hormone-associated prognostic signature could
suggest the use of adjuvant endocrine therapy.
Lung tumors express estrogen receptors (ERs) [3–11], are inhibited
by antiestrogens [6,7], and are responsive to the steroid hormones
β-estradiol [5,9,11] and progesterone [12]. Hormone pathways affect
lung cancer survival [13–16]. NSCLCs are often ERβ positive [13],
and β-estradiol both induces proliferation in NSCLCs [9] and
promotes lung cancer in animal models [17]. Thus, there are
similarities between breast cancer and lung cancer in how estrogen
controls tumor progression. We hypothesized that the prediction
analysis of microarray 50 (PAM50) gene panel developed for
classification of breast cancer into subtypes with different clinical
behavior [18], and especially useful in predicting survival of
ERα-positive breast cancer [19], may also inform prognosis in lung
cancer. We examined the prognostic ability of the PAM50 gene panel
in NSCLC using data from a stage I NSCLC cohort, an independent
all-stage NSCLC cohort consisting only of ERβ-positive cases, and
The Cancer Genome Atlas (TCGA) data. We also investigated the
relationship between tumor mRNA and protein expression level for
several PAM50 genes, and the relationship of protein expression to
detection of the full-length active isoform of ERβ protein (ERβ-1) by
immunohistochemistry (IHC). Pathway analysis was used to explore
signaling interactions predicted to be involved in the function of
informative PAM50 genes.Table 1A. Cohort 1: Stage I NSCLC (N = 104)
All Cases (N = 104) ERβ-Positive Cases (N = 35)
Age (mean ± SD) 68.2 ± 9.2 68.5 ± 9.5; n.s.
Sex
Female 57 (54.8%) 20 (57.1%); n.s.
Male 47 (45.2%) 15 (42.9%)
Stage
IA 37 (35.6%) 8 (22.9%); n.s.
IB 67 (64.4%) 27 (77.1%)
Histology
Adenocarcinoma 78 (75.0%) 17 (48.6%); P = .005
Squamous cell 26 (25.0%) 18 (51.4%)
Smoking history
Active 36 (34.6%) 18 (51.4%); n.s.
Former 60 (57.7%) 17 (48.6%)
Never 8 (7.7%) 0 (0%)
Median DFS (years)
All cases 6.32 (4.31, Inf) 4.31 (3.27, Inf) ; n.s.
Adenocarcinoma 6.95 (4.03, Inf) 6.30 (3.35, Inf)
Squamous cell 6.00 (3.54, Inf) 3.64 (1.10, Inf)
ERβ Allred score
High (Allred score N4) Not applicable 20 (57.1%)
Low (Allred score ≤ 4) Not applicable 15 (42.9%)
n.s., not significant.
95% Confidence interval.Material and Methods
Analysis of PAM50 mRNA Gene Expression in
NSCLC Patient Cohorts
We examined the relationship between disease-free survival (DFS)
and expression of the PAM50 genes [18,19] in a cohort of 104 stage I
NSCLCs (cohort 1, Table 1). Cases were selected from the University
of Pittsburgh Lung Cancer SPORE Tissue Bank based on the
following criteria: tumor tissue originated from a completely resected
primary stage I adenocarcinoma or squamous cell lung cancer
diagnosed between 1998 and 2009; smoking history, age at diagnosis,
sex, presence or absence of pleural invasion, and outcome were
recorded; and no neoadjuvant therapy was given. To minimize
survival bias, only tumors resected within 3 months of an incident
biopsy-proven lung cancer diagnosis were included. Of 140 stage I
cases meeting these criteria, 104 cases (Table 1) had fresh-frozen
banked lung cancer tissue available for RNA isolation. Intraoperative
brachytherapy status and adjuvant treatment status were known.
A minority of patients received these therapies, and they were not
significantly associated with prognosis. Age at diagnosis, sex, smoking
history, pleural invasion, and histology also did not significantly
impact prognosis (data not shown). Outcome data were obtained
from the University of Pittsburgh Cancer Institute Cancer Registrar
(http://cancerregistrynetwork.upmc.com/). DFS was calculated from
date of complete surgical resection to the first documented detectable
malignancy related to the resected lung cancer.
Sections of each tumor were examined by a board-certified
pathologist (S.D.); diagnosis, staging, and adequacy of tumor tissue
were confirmed. The American Joint Committee on Cancer seventh
edition staging guidelines were followed. RNA was isolated from
frozen tumor tissue and, after passing quality checks, was used to
assess mRNA expression with the Illumina Human HT-12 v4
BeadChip. Microarray data are available in the ArrayExpress databaseTable 1B. Cohort 2: All-Stage ERβ Positive NSCLC (N = 63)
Age (mean ± SD) 69.38 ± 8.58
Sex
Female 30 (47.6%)
Male 33 (52.4%)
Stage
IA 12 (19.0%)
IB 18 (28.6%)
IIA/IIB 12 (19.0%)
IIIA/IIIB 15 (23.8%)
IV 6 (9.6%)
Histology
Adenocarcinoma 26 (41.3%)
Squamous cell 29 (46.0%)
Large cell/undifferentiated 6 (9.5%)
Other 2 (3.2%)
Smoking history
Active 24 (38.1%)
Former 32 (50.8%)
Never 2 (3.2%)
Unknown 5 (7.9%)
Median PFS (years)
All cases 1.86 (1.21, Inf)
Adenocarcinoma 1.71 (1.21, Inf)
Squamous cell 1.96 (0.997, Inf)
ERβ Allred score
High (Allred score N4) 32 (50.8%)
Low (Allred score ≤ 4) 31 (49.2%)
95% Confidence interval.
Table 2. Differential Expression of PAM50 Genes Selected During 10× Cross-Validation of
Survival Analysis
Gene Times Selected Relative Expression in High-Risk Survival Group Direction
KRT14 1 1.51 Upregulated
KRT17 1 1.36 Upregulated
CDH3 1 1.55 Upregulated
PHGDH 1 0.72 Downregulated
CCNE1 1 1.10 Upregulated
TMEM45B 1 1.46 Upregulated
SFRP1 1 1.25 Upregulated
ACTR3B 1 0.51 Downregulated
EXO1 1 2.11 Upregulated
NAT1 2 1.98 Upregulated
ERBB2 2 1.11 Upregulated
MLPH 4 1.67 Upregulated
CDCA1 4 1.27 Upregulated
GRB7 5 2.36 Upregulated
MIA 6 1.56 Upregulated
MYC 7 1.29 Upregulated
PGR 8 0.84 Downregulated
FGFR4 9 1.56 Upregulated
CXXC5 9 2.06 Upregulated
FOXC1 10 1.29 Upregulated
Using a marginal P b .1 as cutoff.
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mRNA data were subjected to background subtraction and quantile
normalization. Supervised principal component analysis (PCA) was
conducted, first to evaluate the ability of all the PAM50 genes to associate
with DFS and second by using the top genes selected using the marginal
P value of .1 as cutoff. All results were subjected to 10-fold cross-validation,
including the feature selection step.
A second cohort of 63 lung cancer cases representing all histologies
and stages (cohort 2, Table 1B) was used to confirm PCA results from
cohort 1. Previously published IHC data of ERβ-1 expression [13]
were available for all 63 cases in cohort 2; all were positive for ERβ
(Allred score N0). Outcome data for these patients have previously
been used for analysis of survival related to ERβ IHC scores [13]. The
63 cohort 2 cases are a subset of the 183 cases in the published study
[13]; they are ERβ-positive cases for which sufficient tumor material
remained for RNA isolation. Because cohort 2 contains some patients
who were never disease free, progression-free survival (PFS) instead of
DFS was used. PFS was calculated from the date of resection to the
first documentation of malignancy for disease-free patients or from
diagnostic biopsy to first documented date of progression for patients
who were never disease free. Microarray data are available in the
ArrayExpress database under accession number E-MTAB-3665.
Analysis Using TCGA Data Sets
The cBioPortal for Cancer Genomics Web site, http://www.
cbioportal.org/public-portal/, was used to access TCGA mRNA
expression data. The provisional RNASeq V2 RSEM z-score for each
gene was used. The z-score (positive or negative) represents a
normalized relative expression level and was used as a surrogate for the
mRNA level. Data for all 50 PAM50 genes were available from the
TCGA cases. Overall survival (OS) data and tumor stage, if available
(adenocarcinoma study), were downloaded. For adenocarcinoma,
203 cases had mRNA expression and OS data; for squamous cell
carcinoma, 220 cases had these data. DFS or PFS data were not
available for most TCGA cases. The cBioPortal was used to assess
correlation of expression among the PAM50 genes and value of
individual genes in assessing OS based on a z-score cutoff of +1.5,
+2.0, or +3.0. Association of OS with individual PAM50 gene
z-scores in TCGA data (by Kaplan-Meier survival analysis and log
rank test) was analyzed using the R package on the cBioPortal
website. Data were accessed from the cBioPortal between October 1,
2014, and December 15, 2014.
Pathway/Network Analysis
The Ingenuity Pathway Analysis (IPA) software program (version
21901358) was used to explore pathway relationships. Relative
expression observed in the poor-survival group compared with the
better-surviving group for each gene, as determined in cohort 1, was
entered for analysis. Predicted interacting networks among the genes
were generated, as well as canonical signaling systems, upstream
regulators, functions or diseases affected by these genes, and P values
for the likelihood of associations. The IPA program was accessed
between December 12, 2014, and December 31, 2014.
Immunohistochemistry
Protein expression was measured by staining formalin-fixed,
paraffin embedded (FFPE) tissues with the following antibodies
and dilutions: ERβ-1 (AbD Serotec; MCA 1974ST; 1:40; detects the
full-length isoform of ERβ), HER2 (Thermo Scientific; MS-730;1:400), HER3 (Santa Cruz Biotechnology; sc-285; 1:100), c-Myc
(Abcam; ab32072; 1:50), and cyclin E (Abcam; ab9517; 1:100).
Immunoreactive cells were visualized with diaminobenzidine chro-
mogenic substrate and counterstained with hematoxylin. Positive and
negative controls were included. Exclusion of the primary antibody
was used for negative controls. Breast carcinoma tissue was used as a
positive control. Each section was scored semiquantitatively by a
board-certified pathologist (S.D.) under blinded conditions. IHC
results of ERβ-1 for cases in cohort 2 were previously reported using
the Allred scoring system [13]. The H-score system was used for
c-Myc, HER3, and cyclin E staining [20]. HER2 expression was
scored 0 to 3 as for breast cancer based on percentage of positively
stained tumor cells [21]. Cases used for IHC (N = 91; 42 from cohort
1, 26 from cohort 2, and an additional 23 stage I cases with FFPE
tumor tissue that met the eligibility criteria for inclusion in cohort 1
but did not yield mRNA of sufficient quality for gene expression) had
sufficient FFPE tumor tissue for analysis and gave interpretable results
in scoring for ERβ-1 and at least one other protein (CCNE1, MYC,
HER2. and HER3).
Statistical Analysis
To evaluate the prognostic ability of PAM50 genes, we applied
PCA to the gene expression matrix. The prognostic values of the top
three principal components (PCs) were evaluated. Using the median
of each PC score as the cutoff, the cohort was divided into two groups.
Log rank tests were used to compare survival of these two groups. To
evaluate the prognostic value of top (selected) PAM50 genes, we used
supervised PCA as detailed by Bair and Tibshirani [22]: first, the
marginal association of each gene is evaluated by Cox proportional
hazard; next, only markers that reached a marginal P value of .1 or less are
subjected to PCA analysis to determine the prognostic value. To avoid
overfitting, allmodelswere evaluatedby10-fold cross-validation.Whenusing
only the top genes (evaluated by marginal association of the gene and
outcomes), the feature selection step is included in the cross-validation cycles.
To evaluate the association between the ERβ status (positive versus
negative) and protein expression of other genes assessed by IHC
(positive or negative), two-sided Fisher’s exact tests were used. t tests
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between samples that exhibited high and low protein expression level
(assessed by IHC). For this analysis, IHC score of each protein was
dichotomized into high versus low groups. Kaplan-Meier survival
curves were used to evaluate DFS and PFS. Hazard ratios (HRs) and
the corresponding 95% confidence intervals (CIs) were calculated
using Cox proportional hazard models. All tests were two sided,
and RNA expression analyses were conducted using the R software
program (version 3.0.2).
Results
Survival Analysis in Stage I Lung Cancer
In the stage I cohort (cohort 1, N = 104, Table 1A), expression of
three PAM50 genes (CXXC5, FGFR4, FOXC1) individually showed
significant (P b .05) association with DFS (data not shown). Higher
expression of each of these genes was associated with worse survival
(Table 2). The other PAM50 genes were not individually associated
with survival. The top three PCs that described variation in expression
of the PAM50 gene panel were evaluated for association with DFS.
Using PC2, the PAM50 gene panel separated cohort 1 based on DFS,
but the result was not significant (Table 3). The relationship with
DFS was stronger in cohort 1 using only seven PAM50 genes, each
marginally associated with DFS at P b .1 in at least five cycles
(Table 2) during the 10× cross-validation (Table 3). These genes
(GRB7, MYC, MIA, CXXC5, PGR, FGFR4, and FOXC1) show the
strongest association with DFS in the stage I cohort. The HR of the
worse prognostic group using the seven genes was 2.08 (95% CI:
1.18-3.66) using PC2, P = .01 (Table 3).
Directionality of change for the genes selected at least once during
cross validation is shown in Table 2. The mRNA expression of GRB7,
MIA, MYC, FGFR4, CXXC5, and FOXC1 were upregulated in
high-risk cases, whereas PGR mRNA expression was downregulated.
Eleven PAM50 genes marginally selected were upregulated and two
were downregulated in high-risk compared with low-risk cases.
Kaplan-Meier survival curves of cohort 1 using the seven informative
genes (not shown) showed that median DFS of the high-risk group
was 4.50 years (N = 55, 30 events), whereas median DFS in the
low-risk group was 6.95 years (N = 49, 20 events, P = .01). Cohort 1
was not selected for ERβ-positive lung tumors, but based on our
previous work [13] and the literature [14,15], we expect 65% to
75% of NSCLCs to be ERβ positive. We did not find that the
PAM50 genes clustered NSCLCs (either adenocarcinoma or squamous
cell carcinoma) into subtypes as has been found for breast cancer.Table 3. PCA of Survival of the PAM50 Gene Panel in NSCLC Cohorts
Group Model HR CI P Value
Cohort 1
Stage I, DFS (N = 104) (discovery Set)
All genes 1.51 (0.86, 2.67) .15
Seven-gene model 2.08 (1.18, 3.66) .01
Cohort 1 subgroup
Stage I, ERβ positive, DFS (N = 35)
All genes 2.47 (0.89, 6.81) .080
Seven-gene model 2.44 (0.99, 5.99) .050
Cohort 2
All stages, PFS ERβ positive (N = 63)
All genes 1.84 (0.91, 3.75) .091
Seven-gene model 2.26 (1.10, 4.65) .026
TGCA Adenoca all stages, OS
(N = 203)
All genes 2.14 (1.27, 3.61) .004
Seven-gene model 1.42 (0.86, 2.35) .16
TGCA Adenoca stage I, OS
(N =101)
All genes 3.17 (1.26, 7.97) .01
Seven-gene model 1.39 (0.56, 3.43) .48
TGCA Sq cell ca OS
(N = 220)
All genes 1.66 (1.09, 2.54) .018
Seven-gene model 1.62 (1.06, 2.47) .026
Adenoca, adenocarcinoma; Sq cell ca, squamous cell carcinoma.
P b .05.Therefore, we could not use the risk score algorithm developed for
breast cancer in survival analysis.
Relationship of PAM50 Genes to ERβ-Positive Status
PAM50 genes were subsequently analyzed in a subset of 35 cases
from cohort 1 (Table 1A) for which ERβ IHC was found to be
positive (Allred score N0). We have previously found little or no ERα
protein in NSCLC when using IHC antibodies validated for ERα
determination in breast cancer patients [13]. Therefore, only ERβ was
analyzed. The ERβ-positive subset did not significantly differ from
the entire cohort by age, sex, stage, smoking history, or survival
(Table 1A) but did differ by histology: 48.6% were squamous cell
carcinoma compared with 25% in cohort 1 (P b .005). The PAM50
panel was prognostic in the ERβ-positive subset with marginal
significance (HR 2.47 [95% CI: 0.89-6.89], P = .080, Table 2),
whereas the seven-gene panel significantly associated with DFS in
ERβ-positive stage I cases (HR 2.44 [95% CI: 0.99-5.99], P = .050,
Table 2). We also stratified the cases by ERβ score into high and low
subgroups. Although the ERβ high cases showed better separation of
survival groups using either the PAM50 panel or the seven-gene
model compared with the ERβ low cases (HR N6, P b .005), these
results were unstable because of small sample size, and this analysis
may be overfit (data not shown).
For the ERβ-positive stage I cases, Kaplan-Meier survival curves
using all PAM50 genes showed that median DFS in the high-risk
group was 3.27 years (N = 18, 16 events), whereas median DFS in the
low-risk group was 6.6 years (N = 17, 5 events, Figure 1A). Using the
seven-gene model with ERβ-positive stage I cases, median DFS was
2.37 years (N = 14, 13 events) in the high-risk group compared with
6.6 years in the low-risk group (N = 21, 8 events, Figure 1B).
Pathway Analysis of Informative PAM50 Genes
Using IPA software, we identified networks likely to be involved in
the prognostic signatures. The relative expression of the 20 genes
retained at least once in PCA cross-validation (Table 2) was evaluated,
as well as the seven-gene signature. Using 20 genes, 3 interacting
networks were identified that included cancer, reproductive systems
disease, and breast cancer proliferation as top functions (Supplemen-
tal Table 1). Neuregulin signaling, E2-mediated S phase entry, and
HER2/HER3 signaling were among the top 10 canonical pathways.
Using the seven-gene signature, only one interacting network was
identified (illustrated in Supplemental Figure 1). Cell migration,
proliferation of tumor cells, and cancer were the top three functions for this
network, and STAT3, neuregulin signaling, andE2-mediated S phase entry
were among the top 10 canonical pathways (Supplemental Table 1).
Likely top upstream regulators for the 20-gene signature were related to
hormones and the HER2 or HER3 pathway, and for some regulators, an
activation score could be computed. These included R5020 (a progestin;
activation score of 1.96), trastuzumab (a neutralizing antibody for HER2),
HOXB4 (a homeobox transcription factor that regulatesMYC and PGR),
NRG-1 (a ligand for HER3/HER4; activation score of 1.98), the ER
letrozole (an aromatase inhibitor), and β-estradiol (activation score of 2.14).
The cell cycle gene cyclin D (CCND1) was also an upstream regulator. In
the seven-gene signature, hormonal agents were found as significant
upstream regulators: premarin (an estrogen) as well as the selective ER
modulator bazedoxifene. Letrozole, the ER, and NRG1 also remained in
the model as predicted top upstream regulators of the seven-gene network
(Supplemental Table 1). Activation scores could not be predicted in the
seven-gene analysis because of the small number of genes analyzed.
Figure 1. Kaplan-Meier survival curves of NSCLC cases dichotomized using PCA of PAM50 genes. (A) DFS of ERβ-positive subset from
cohort 1 (stage I NSCLC) using all 50 PAM50 genes (N = 35). (B) DFS of ERβ-positive subset from cohort 1 (stage I NSCLC) using the
seven-gene model (N= 35). (C) PFS of ERβ-positive subset from cohort 2 (all-stage NSCLC) using all 50 PAM50 genes (N= 63). (D) PFS of
ERβ-positive subset from cohort 2 (all-stage NSCLC) using the seven-gene model (N = 63).
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(Supplemental Figure 1) contains the ER, PGR, and the
ERBB (HER) family of proteins, as well as β-estradiol, AKT,
MAPK, ERK1/2, and JNK, suggesting interactions of hormone
receptors that involve cytoplasmic signaling with the ERBB/HER
receptors. The upstream regulator analysis suggests the HER3 ligand
NRG1 is a driver of this network. Nongenomic signaling involving
cross talk between β-estradiol and EGFR/HER1 has been described
in NSCLC by us and others [23–25]; the PAM50 model suggests that
other HER family members are also important in cross talk with
steroid hormones in NSCLC.
Relationship of PAM50 Gene mRNA Expression to
Protein Expression
To confirm mRNA expression differences at the protein level, we
examined several genes (HER2, CCNE1, and MYC) by carrying out
IHC in the same FFPE blocks used for ERβ determination. These
proteins were chosen because they contributed to the top
differentially expressed genes from Table 2 and because reliable
antibodies were available for IHC. Comparing IHC scores to the
mRNA level measured by the Illumina Bead Chip array, we observed
significant associations between mRNA levels and IHC scores for
CCNE1 (P = .001) and MYC (P = .0003, Supplemental Figure 2).For HER2, the mRNA expression level was often very low, and there
was a higher mRNA level with IHC scores of 2 (the threshold for an
HER2-positive assessment in breast cancer) compared with b2, but it
did not reach statistical significance (Supplemental Figure 2).
Association of ERβ IHC Expression with IHC Expression
of PAM50 Genes
We additionally evaluated the relationship between IHC scores for
CCNE1, MYC, and HER2 and the status of ERβ protein (ERβ
positive, Allred score N0, compared with ERβ negative, Allred score
0). We observed a significant positive relationship between a
detectable level of CCNE1, MYC, and HER2 (IHC scores N0)
and ERβ-positive status. A positive result for staining of CCNE1 was
more frequently observed in the ERβ-positive group than the
ERβ-negative group (59.0% vs 33.3%, P = .027, Table 4). A similar
result was observed for MYC in the ERβ-positive compared with
ERβ-negative group (56.1% vs 20.0%, P = .001). For HER2, an
IHC score greater than 0 was observed in 70.2% of ERβ-positive
cases compared with 34.5% of ERβ-negative cases (P = .002,
Table 4). Using the clinical definition of HER positivity (a score of 2
or more), we observed that 35.1% of ERβ-positive cases fell in this
group compared with 6.9% of ERβ-negative cases (P = .013,
Table 4). Because HER3 was predicted to interact in a network with
Table 4. Association of IHC Scores for CCNE1, MYC, HER2, and HER3 with ERβ
ERβ Group CCNE1
Positive
P MYC Positive P HER2 Positive P HER2
Clinically
Positive (+2)
P HER3 Positive P HER2+2
and HER3
Positive (N0)
P HER2 &
HER3
Negative
P
0 N0 0 N0 0 N0 b2 2 0 N0 No Yes No Yes
Positive (Allred score N0) 25 36 59.0% .027 25 32 56.1% .001 17 40 70.2% .002 37 20 35.1% .004 38 22 36.7% .64 45 12 21.1% .052 43 14 24.6% .008
N = 61 N = 57 N = 57 N = 57 N = 60 N = 57 N = 57
Negative (Allred score =0) 20 10 33.3% 24 6 20.0% 19 10 34.5% 27 2 6.9% 21 9 30.0% 28 1 3.4% 13 16 55.2%
N = 30 N = 30 N = 29 N = 29 N = 30 N = 29 N = 29
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relationship with ERβ positive cases was not found. However, when
HER2 and HER3 (receptors that often heterodimerize with each
other) were considered together, a greater proportion of ERβ-positive
cases were both clinically positive for HER2 (score of 2) and positive for
HER3 compared with ERβ-negative cases (21.1% vs 3.4%, P = .052).
ERβ-positive cases were less likely than ERβ-negative cases to be negative
for both HER2 and HER3 (24.6% vs 55.2%, P = .008, Table 4).
There was also a significant relationship between HER3 staining
and HER2 score (P = .026). For a HER2 score of 0, 6 of 37 cases
(16.2%) had HER3 scores of N0. For a HER2 score of 1, 12 of 27
(44.4%) had HER3 scores N0. For a HER2 score of 2, 13 of 22 cases
(59.1%) had HER3 scores N0.
Performance of PAM50 Panel in All-Stage NSCLC Cohort
To verify the results in cohort 1, we examined PAM50 genes in a
separate cohort of 63 NSCLC cases, which included all stages and
histologic types (cohort 2, Table 1B). These cases were known to be
ERβ positive based on Allred scores N0 using the ERβ-1-specific
antibody, and an example of the staining has been published
previously [13]. Compared with cohort 1, cohort 2 had significantly
fewer stage I cases (P b .0001) and contained more squamous cell
carcinoma (P b .008). Using all 50 PAM50 genes, cohort 2
marginally separated into two survival groups, whereas the seven-gene
model was prognostic (HR 2.64 [95% CI: 1.17-5.11], P = .026,
Table 3). Kaplan-Meier survival curves using all PAM50 genes
showed that in the high-risk group, median PFS was 0.99 years (N =
28, 16 events), whereas in the low-risk group, median PFS was 2.75
years (N = 35, 15 events, Figure 1C). Using the seven-gene model,
median PFS was 1.06 years (N = 33, 20 events) in the high-risk group,
whereas median PFS was not reached in the low-risk group (N = 30,
11 events, Figure 1D).
Survival Analysis of PAM50 Genes in the TCGA
NSCLC Cohorts
In TCGA NSCLC publically available RNASeq V2 RSEM data,
the most common alteration reported for PAM50 genes was
overexpression (z-score threshold of +1.5 or higher). Fewer than
4% of TCGA cases had negative z-scores for any of the PAM50
genes. In lung adenocarcinoma, many genes such as MKI67, ANLN,
NDC80, and EXO1 showed highly significant correlations (P b .0001
or better) with up to 15 other PAM50 genes, suggesting that these
genes are concordantly expressed (data not shown). In lung
adenocarcinoma, overexpression of 23 PAM50 genes was indepen-
dently prognostic for OS by log rank test at P b .05 or better
(Supplemental Table 2).
Analysis of TCGA squamous cell carcinoma also showed positive
correlations among many PAM50 genes at P b .05. Several genes(MKI67, ANLN, EXO1, and NDC80) showed significant positive
correlations with up to 15 other PAM50 genes, suggesting that
PAM50 genes are also expressed together in lung squamous cell
carcinoma (data not shown). In the squamous cell carcinoma data set,
11 PAM50 genes were independently prognostic for survival at P b .05
or better when overexpressed (Supplemental Table 2).
We next examined the PAM50 panel and the seven-gene signature
by PCA in the TCGA cohorts using the z-scores as a surrogate for
mRNA expression level. There are no data on ERβ IHC scores for
these cases, so assessment in an ERβ-positive subgroup could not be
done. In adenocarcinoma, the complete PAM50 panel was prognostic
for OS (HR 2.14 [95% CI: 1.27-3.61], P = .004, Table 3). Survival
curves showed that median OS was 32.7 months for the poor-survival
group and 52.5 months for the better-surviving group (Figure 2A).
The seven-gene panel was not informative in the TCGA adenocar-
cinoma cohort (Table 3). Stage I TCGA cases were also analyzed
separately. The 50-gene signature was informative (HR 3.17 [95%CI:
1.26-7.97], P = .01), but the 7-gene signature was not. Kaplan-Meier
survival curves using all 50 genes (Figure 2B) showed that the
poor-surviving stage I group reached median OS at 44.4 months,
whereas the better-surviving group reached median OS at 76.2
months. In squamous cell carcinoma, both the all-gene model and the
seven-gene model gave significant results in OS associations: HR of
1.66 (95% CI: 1.09-2.54, P = .018) and 1.62 (95% CI: 1.06-2.47,
P = .026, Table 3), respectively. Median OS was 32.8 and 71.3
months in the high- and low-risk groups, respectively, by the all-gene
model (Figure 2C) and 23.5 and 38.1 months, respectively, in the
seven-gene model (Figure 2D).
Discussion
PAM50 genes separate breast cancer into five subtypes with varying
biological behavior and outcome [18]. PAM50 genes identify both
ERα-positive and -negative breast cancer cases belonging to these
subtypes [18], but the panel contains many estrogen-related genes
and has proven extremely useful in survival analysis of ERα-positive
cases in different therapeutic settings [19,26,27]. PAM50 risk scores
based on assignment to an intrinsic subtype can predict risk of
recurrence and poor survival after endocrine therapy in ERα-positive
breast cancer [19,26]. PAM50 risk scores can also supplement IHC
determinations of ER, PGR, and HER2 in breast cancer for better
prediction of recurrence [27]. We did not find that PAM50 genes
separated NSCLC into different subtypes, and the three genes whose
overexpression had the highest relationship to NSCLC survival are
markers for three different breast cancer subtypes with different
expected outcomes: HER2-enriched (FGFR4), basal-like (FOXC1),
and luminal B (CXXC5), suggesting that the breast cancer subtypes
are not recapitulated in NSCLC. The prognostic value of PAM50
genes in NSCLC does appear to be related to hormone pathways,
Figure 2. Kaplan-Meier survival curves cases in TCGA cohorts dichotomized using PCA of PAM50 genes. (A) OS in the model using all
50 PAM50 genes in all stages of adenocarcinoma (N=203). (B) OS in themodel using all 50 PAM50 genes in stage I adenocarcinoma only
(N = 101). (C) OS in the model using all 50 PAM50 genes in all squamous cell carcinoma cases (N = 220). (D) OS using the seven-gene
model in all squamous cell carcinoma cases (N = 220).
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median survival was somewhat better in cases known to be ERβ
positive than in unselected cases. ER and PGR pathways were
predicted to be involved in interactions among PAM50 genes
informative for NSCLC survival. ERβ status was related to protein
expression of MYC, CCNE1, and HER2.
Cross-validation of PCA results in stage I NSCLC identified seven
genes that most often retained survival associations during the
discovery phase. These genes were prognostic in stage I cases
unselected for ERβ status and also performed well in the ERβ-positive
subset where a two-fold difference in median DFS was observed. In
ERβ-positive NSCLC of all stages, the difference in median PFS
conferred by these seven genes could not be calculated because the
low-risk group did not reach 50% progression.
Pathway analysis suggested that the seven informative PAM50
genes participate in estrogen and HER2/HER3 signaling. HER2
protein was detected more frequently in cases that were ERβ positive.
HER2 level was also a factor in the extent of HER3 protein
expression. The interactive network involving the seven genes
included PGR, β-estradiol, and signaling molecules downstream of
HER family proteins. HER2 activation has been reported to
phosphorylate cytoplasmic PGR, causing its proteosomal degradation[28]. Low PGR was associated with more aggressive breast cancers
that were driven by HER signaling (28), a mechanism that could also
be operative in lung cancer. Our data suggest that interactions
between hormonal and HER signaling define more aggressive lung
tumors.
Many PAM50 genes were individually prognostic in the TCGA
data and were expressed concordantly, suggesting that PAM50 genes
contain biologically meaningful information in NSCLC. Although no
ERβ IHC data are available from these cases, the literature suggests
[13–15] that the majority of TCGA cases would be ERβ positive if
analyzed. In these large data sets, the PAM50 model using all genes
was prognostic in both data sets, whereas the prognostic ability of the
seven-gene signature was not reproduced in TCGA adenocarcinoma
data. In squamous cell carcinoma, the 7-gene and 50-gene panels
both separated lung tumors into survival groups. The seven-gene
signature identified squamous cell carcinoma TCGA patients with a
median survival of less than 2 years.
In TCGA data, the proportion of lung adenocarcinomas and
squamous cell carcinomas overexpressing genes in the seven-gene
signature was similar, as was the proportion of tumors displaying
amplified, mutated, or overexpressed ERBB2/HER2, HER3, and
NRG1. Thus, the interacting network predicted for the seven-gene
824 Prognostic Ability of PAM50 Gene Panel in NSCLC Siegfried et al. Neoplasia Vol. 17, No. 11, 2015signature does not seem to be preferentially dysfunctional in squamous
cell carcinoma compared with adenocarcinoma. Although we did
not previously find any difference in extent of ERβ between
adenocarcinoma and squamous cell carcinoma [13], it is possible the
ERβ-HER2/HER3 interaction may be a stronger driver of progression
in squamous cell carcinoma than in adenocarcinoma. HER2 has
recently been found as a prognostic marker in squamous cell carcinoma
of the head and neck [29].
HER2 has no ligand binding domain but heterodimerizes with
HER3 after HER3 is activated by ligands such as NRG1. Cross talk
between ER and EGFR/HER1 has been reported in both breast and
lung cancer [23,24], occurring through the release of EGFR ligands
such as HB-EGF and amphiregulin after being stimulated by
estrogen. Because activated HER1 heterodimerizes with HER2 and
HER2 heterodimers produce more durable signaling [29], HER2
may be an important contributor in EGFR cross talk with ERβ.
Recent reports suggest correlations between ER-positive breast cancer
and expression of both HER2 and HER3, whereas cross talk between
ER and HER2 is reported to contribute to resistance to endocrine
therapies [30]. Our results point to release of NRG1 or other ligands
for the HER family of receptors, stimulated through ERβ, in causing
HERs to drive NSCLC aggressive behavior. Although ERβ is often
thought of as an antiproliferative molecule in breast cancer, it is
usually studied in the context of ERα expression [31]. In studies that
examined ERα-negative breast cancer expressing ERβ, ERβ was
associated with proliferation [31], and ERβ-positive patients lacking
ERα responded to tamoxifen [31]. Because most lung tumors have
little or no functional ERα [13], ERβ may assume many of the
proliferative functions of ERα.
This study provides evidence that genes within the PAM50
signature have prognostic value in lung cancer, especially among
squamous cell carcinoma. Strengths of the study include ability to
reproduce the results in different NSCLC cohorts and validation of
pathway ions at the protein level. Pathways that were delineated by
the most prognostic genes also involved biologically plausible
interactions that included hormone receptor action. Limitations of
the study include use of case cohorts with different stage and
histological distributions, need to define survival by different
parameters in the different cohorts, and lack of ERβ IHC information
in TCGA data. Like most studies that look at DFS and PFS, we
assigned time of progression to the visit at which it was detected,
which may have biased our results. mRNA profiling data were used in
the Pittsburgh cohorts, whereas RNA Seq data were used for TCGA
data. These limitations could have contributed to inability to
reproduce all findings in the TCGA adenocarcinoma data.
HER2 overexpression warrants further investigation as a target in
lung cancer even in the absence of gene amplification. Further study
of interactions between HER2 and HER3 proteins and ER signaling
in NSCLC, as well as co-targeting the ER and HER pathways in
NSCLC, is also warranted. Expression of ERβ and PAM50 genes
might also be useful in identifying NSCLC patients most likely to
benefit from endocrine therapy in the adjuvant setting.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.11.002.
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